{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:46:15Z","timestamp":1793655975258,"version":"4.5.1"},"reference-count":98,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a (FMM)","doi-asserted-by":"publisher","award":["P177122021"],"award-info":[{"award-number":["P177122021"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>High prevalence of both criteria and extra-criteria antiphospholipid antibodies (aPL) has been reported in COVID-19 patients. However, the differences in aPL prevalence decreased when an age-matched control group was included. The association of aPL with thrombotic events in COVID-19 is very heterogeneous. This could be influenced by the fact that most of the studies carried out were conducted on small populations enriched with elderly patients in which aPL was measured only at a single point and they were performed with non-standardized assays. The few studies that confirmed aPL in a second measurement showed that aPL levels hardly changed, with the exception of the lupus anticoagulant that commonly reduced. COVID-19 coagulopathy is an aPL-independent phenomenon closely associated with the onset of the disease. Thrombosis occurs later in patients with aPL presence, which is likely an additional prothrombotic factor. B2-glycoprotein deficiency (mainly aPL antigen caused both by low production and consumption) is very common during the SARS-CoV2 infection and has been associated with a greater predisposition to COVID-19 complications. This could be a new prothrombotic mechanism that may be caused by the blockage of its physiological functions, the anticoagulant state being the most important.<\/jats:p>","DOI":"10.3390\/ijms23094946","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T05:44:07Z","timestamp":1651297447000},"page":"4946","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7177-667X","authenticated-orcid":false,"given":"Manuel","family":"Serrano","sequence":"first","affiliation":[{"name":"Department of Immunology, Healthcare Research Institute I+12, Hospital 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-0163","authenticated-orcid":false,"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, Insititut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-640X","authenticated-orcid":false,"given":"Antonio","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Immunology, Healthcare Research Institute I+12, Hospital 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-492X","authenticated-orcid":false,"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, Insititut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"China medical treatment expert group for COVID-19 2020. Clinical Characteristics of coronavirus disease in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e137799","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2020.06.029","article-title":"The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management","volume":"194","author":"Diamond","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2666-5247(20)30115-4","article-title":"Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: A post-mortem study","volume":"1","author":"Hanley","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104362","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2018-04-841585","article-title":"Hypoxia downregulates protein S expression","volume":"132","author":"Pilli","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcrc.2017.09.035","article-title":"Increased DNA damage and increased apoptosis and necrosis in patients with severe sepsis and septic shock","volume":"43","author":"Bahar","year":"2018","journal-title":"J. Crit. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic Vascular Endothelial Cells Become Procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-019-0205-9","article-title":"Hypoxia and HIF activation as a possible link between sepsis and thrombosis","volume":"17","author":"Evans","year":"2019","journal-title":"Thromb. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.200606027","article-title":"Novel cell death program leads to neutrophil extracellular traps","volume":"176","author":"Fuchs","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_17","first-page":"366","article-title":"Neutrophil Extracellular Traps Go Viral","volume":"7","author":"Raftery","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of auto-immunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"838011","DOI":"10.3389\/fimmu.2022.838011","article-title":"NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677040","article-title":"Neutrophil Extracellular Traps in Arterial and Venous Thrombosis","volume":"45","author":"Laridan","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., and Liu, H. (2020). Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv.","DOI":"10.1101\/2020.03.29.20041962"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical Hemolytic Uremic Syndrome: A Brief Review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"584241","DOI":"10.3389\/fimmu.2020.584241","article-title":"Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome","volume":"11","author":"Borghi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/joim.13123","article-title":"Viral infections and their relationship with catastrophic antiphospholipid syndrome: A possible pathogenic mechanism of severe COVID-19 thrombotic complications","volume":"288","author":"Bailey","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1182\/blood-2005-05-2048","article-title":"Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus","volume":"106","author":"Male","year":"2005","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2019.00376","article-title":"Reliability of Lupus Anticoagulant and Anti-phosphatidylserine\/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study","volume":"10","author":"Sciascia","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/TP.0000000000001199","article-title":"The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-beta-2-Glycoprotein I as a Predictor of Graft Thrombosis after Renal Transplantation","volume":"101","author":"Morales","year":"2017","journal-title":"Transplantation"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cabrera-Marante, O., Rodriguez de Frias, E., Serrano, M., Lozano Morillo, F., Naranjo, L., and Gil-Etayo, F.J. (2020). The Weight of IgA Anti-beta2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238972"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study","volume":"7","author":"Pengo","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2019.11.029","article-title":"Anti-beta2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome","volume":"185","author":"Liu","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant)","volume":"20","author":"Cervera","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1023\/B:JOCI.0000018058.28764.ce","article-title":"Antiphospholipid Syndrome Infectious Origin","volume":"24","author":"Blank","year":"2004","journal-title":"J. Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: Understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with COVID-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","first-page":"e73","article-title":"Presence of antiphospholipid antibodies in COVID-19: A case series study","volume":"80","author":"Springall","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","first-page":"754","article-title":"Frequency and clinical correlates of an-tiphospholipid antibodies arising in patients with SARS-CoV-2 infection: Findings from a multicentre study on 122 cases","volume":"38","author":"Gatto","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr2.11245","article-title":"Beta-2-Glycoprotein-I Deficiency could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients with Coronavirus Disease 2019","volume":"3","author":"Serrano","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.41425","article-title":"Antiphospholipid Antibodies in Critically Ill Patients With COVID-19","volume":"72","author":"Xiao","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","first-page":"e2869","article-title":"Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies","volume":"73","author":"Bomze","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/art.41634","article-title":"Antiphospholipid Autoantibodies and Thrombosis in Patients with COVID-19: Comment on the Article by Bertin et al","volume":"73","author":"Frapard","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s10067-020-05180-7","article-title":"High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia","volume":"39","author":"Gazzaruso","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eabd3876","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Gil-Etayo, F.J., Garcinuno, S., Lalueza, A., Diaz-Simon, R., Garcia-Reyne, A., and Pleguezuelo, D.E. (2021). Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, not a Supporting Actor. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080899"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2020.07.016","article-title":"Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?","volume":"195","author":"Siguret","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/jth.14994","article-title":"Antiphospholipid antibodies in patients with COVID-19: A relevant observation?","volume":"18","author":"Devreese","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3855\/jidc.15423","article-title":"The clinical significance of antiphospholipid antibodies in COVID-19 infection","volume":"16","author":"Atalar","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gasparini, G., Canepa, P., Verdiani, S., Carmisciano, L., Cozzani, E., De Grazia, D., Andrea, O., Icardi, G., and Parodi, A. (2021). A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients. Int. J. Immunopathol. Pharmacol., 35.","DOI":"10.1177\/20587384211042115"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e017773","DOI":"10.1161\/JAHA.120.017773","article-title":"High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019","volume":"9","author":"Ferrari","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/annrheumdis-2021-220206","article-title":"Anticardiolipin and other antiphos-pholipid antibodies in critically ill COVID-19 positive and negative patients","volume":"80","author":"Trahtemberg","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2020.06.042","article-title":"The pathogenesis of thromboembolic disease in COVID-19 patients: Could be a catastrophic antiphospholipid syndrome?","volume":"194","author":"Previtali","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2020.05.017","article-title":"Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism","volume":"192","author":"Oblitas","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102822","DOI":"10.1016\/j.autrev.2021.102822","article-title":"Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent","volume":"20","author":"Vollmer","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"687534","DOI":"10.3389\/fimmu.2021.687534","article-title":"Antiphospholipid Antibodies and Infection: Non Nova Sed Nove","volume":"12","author":"Sciascia","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2012.05.006","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome","volume":"12","author":"Mahler","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00001721-199112000-00012","article-title":"Transient lupus anticoagulant induced by Epstein-Barr virus infection. Blood Coagul","volume":"2","author":"Yamazaki","year":"1991","journal-title":"Fibrinolysis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2019.02.008","article-title":"High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening","volume":"176","author":"Wypasek","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_66","first-page":"623","article-title":"The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies","volume":"16","author":"Fields","year":"1989","journal-title":"J. Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"665741","DOI":"10.3389\/fcvm.2021.665741","article-title":"Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke","volume":"8","author":"Naranjo","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.revmed.2008.05.020","article-title":"Antiphospholipid antibodies, antiphospholipid syndrome and viral infections","volume":"30","author":"Sene","year":"2009","journal-title":"Rev. Med. Interne"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1538-7836.2007.02669.x","article-title":"Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases","volume":"5","author":"Swadzba","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1021\/ac403194t","article-title":"Heterogeneity between Diagnostic Tests for IgA anti-Beta2 Glycoprotein I: Explaining the Controversy in Studies of Association with Vascular Pathology","volume":"85","author":"Serrano","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ijlh.12543","article-title":"Evaluation of three fully automated immunoassay systems for detection of IgA anti-beta 2-glycoprotein I antibodies","volume":"38","author":"Serrano","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100610","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS","volume":"39","author":"McDonnell","year":"2019","journal-title":"Blood Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"beta(2)-glycoprotein I, the major target in an-tiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1074\/jbc.M704990200","article-title":"Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members","volume":"283","author":"Maiti","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2012.04.003","article-title":"beta2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity?","volume":"12","author":"Matsuura","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0961203310361352","article-title":"Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome","volume":"19","author":"Matsuura","year":"2010","journal-title":"Lupus"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2010-12-325951","article-title":"Beta(2)-glycoprotein I: A novel component of innate immunity","volume":"117","author":"Agar","year":"2011","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.thromres.2004.07.017","article-title":"Beta 2 glycoprotein I-function in health and disease","volume":"114","author":"Miyakis","year":"2004","journal-title":"Thromb. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: Same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/molehr\/gah058","article-title":"Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice","volume":"10","author":"Robertson","year":"2004","journal-title":"Mol. Hum. Reprod."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jth.12679","article-title":"Identification of APOH polymorphisms as common genetic risk factors for venous thrombosis in the Chinese population","volume":"12","author":"Tang","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_82","first-page":"269","article-title":"Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. Expert Rev","volume":"14","author":"Kolialexi","year":"2017","journal-title":"Proteom"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jri.2013.04.003","article-title":"Trophoblast invasion and oxygenation of the placenta: Measurements versus presumptions","volume":"101\u2013102","author":"Huppertz","year":"2014","journal-title":"J. Reprod. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1469-7580.2008.01036.x","article-title":"Oxygen as modulator of trophoblast invasion","volume":"215","author":"Huppertz","year":"2009","journal-title":"J. Anat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clim.2004.02.014","article-title":"Beta-2 glycoprotein I and its role in antiphospholipid syndrome\u2014Lessons from knockout mice","volume":"112","author":"Miyakis","year":"2004","journal-title":"Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1161\/CIRCULATIONAHA.116.025992","article-title":"Beta2-Glycoprotein I\/IgA Immune Complexes: A Marker to Predict Thrombosis after Renal Transplantation in Patients with Antiphospholipid Antibodies","volume":"135","author":"Serrano","year":"2017","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3389\/fimmu.2018.02644","article-title":"Presence of Immune Complexes of IgG\/IgM Bound to B2-glycoprotein I Is Associated with Non-criteria Clinical Manifestations in Patients with Antiphos-pholipid Syndrome","volume":"9","author":"Perez","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5551\/jat.34488","article-title":"Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events","volume":"23","author":"Serrano","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13054-020-03066-3","article-title":"Beta-2-glycoprotein I as a biomarker for sepsis in critically ill patients in the intensive care unit: A prospective cohort study","volume":"24","author":"Schrijver","year":"2020","journal-title":"Crit. Care"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.1996.446981.x","article-title":"Beta 2-glycoprotein I in thrombosis: Evi-dence for a role as a natural anticoagulant","volume":"93","author":"Brighton","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e14167","DOI":"10.15252\/emmm.202114167","article-title":"High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion","volume":"13","author":"Geyer","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11596-018-1889-y","article-title":"Thrombophilia Caused by Beta2-Glycoprotein I Deficiency: In Vitro Study of a Rare Mutation in APOH Gene","volume":"38","author":"Zhang","year":"2018","journal-title":"Curr. Med. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9150(99)00496-7","article-title":"Beta(2)-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis","volume":"152","author":"Yasuda","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"13817","DOI":"10.1074\/jbc.M010990200","article-title":"Impaired thrombin generation in beta 2-glycoprotein I null mice","volume":"276","author":"Sheng","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/bfgp\/elm008","article-title":"Appearances can be deceiving: Phenotypes of knockout mice","volume":"6","author":"Barbaric","year":"2007","journal-title":"Brief. Funct. Genom. Proteom."},{"key":"ref_97","first-page":"1","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"2022","author":"Knight","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1177\/09612033211062523","article-title":"COVID-19 and antiphospho-lipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)","volume":"30","author":"Wang","year":"2021","journal-title":"Lupus"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/4946\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:04:03Z","timestamp":1760137443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/9\/4946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":98,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23094946"],"URL":"https:\/\/doi.org\/10.3390\/ijms23094946","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}